RNase1 prevents the damaging interplay between extracellular RNA and tumour necrosis factor-α in cardiac ischaemia/reperfusion injury. by Cabrera-Fuentes, HA et al.
1 
 
The Damaging Interplay between Extracellular RNA and 
Tumor-Necrosis-Factor-α in Cardiac Ischemia/Reperfusion Injury: 
Prevention of Cardiomyocyte Death and Heart Failure by RNase1 
        
Hector A. Cabrera-Fuentes1,5, Marisol Ruiz-Meana6#, Sakine Simsekyilmaz7#,  Sawa 
Kostin8, Javier Inserte6, Mona Saffarzadeh1,  Vijith Vijayan3, Ignasi Barba6, Sarah 
Pedretti10, Guillermo Barreto9, Tasneem Adam11, Silvia Fischer1, Günter Lochnit1, Olga 
N. Ilinskaya5, Sebastian P. Galuska1, Eveline Baumgart-Vogt3, Andreas Böning4, 
Sandrine Lecour10, Derek J. Hausenloy11, Elisa A. Liehn7, David Garcia-Dorado6, Klaus 
D. Schlüter2, Klaus T. Preissner1 
 
1Institute of Biochemistry, 2Institute of Physiology, 3Institute of Anatomy and Cell Biology II, 
4Department of Cardiovascular Surgery, Medical School, Justus-Liebig-University, Giessen 
35392, Germany;  
5Kazan Federal University, Department of Microbiology, Kazan 420008, Russian Federation;  
6Hospital Universitari Vall d´Hebron, Laboratorio de Cardiología Experimental, Barcelona 
08035, Spain;  
7Institute of Molecular Cardiovascular Research, RWTH, Aachen 52074, Germany. 
8Core Lab for Molecular and Structural Biology, 9LOEWE Research Group Lung Cancer 
Epigenetics, Max-Planck-Institute, Bad Nauheim 61231, Germany;  
10Hatter Institute for Cardiovascular Research, University of Cape Town, Cape Town 7935, 
South Africa; 
11The Hatter Cardiovascular Institute, University College London, London, WC1E 6HX, 
United Kingdom.  
 
# = Equal second authors 
 
Short title: RNase1 and cardiac ischemia/reperfusion injury 
 
Correspondence address: 
Klaus T. Preissner, PhD    
Depart. Biochemistry, Medical School 
Justus-Liebig-Universität    
Friedrichstrasse 24     
35392 Giessen, Germany 
Tel. +49-641-994-7500; Fax. +49-641-994-7509 
e-mail: Klaus.t.preissner@biochemie.med.uni-giessen.de 
 
 
Total word count: 
Subject codes: 4, 91, 118 
2 
 
Abstract 
Background - Despite optimal therapy, the morbidity and mortality of patients presenting 
with an acute myocardial infarction (MI) remain significant. Here, we investigate extracellular 
RNA (eRNA) as a novel therapeutic targets for protecting the heart against the detrimental 
effect of acute ischemia/reperfusion (I/R) injury. 
Methods and Results - We show that eRNA and tumor necrosis factor- (TNF-), released 
by the myocardium in response to I/R, mediate cardiomyocyte death. In patients subjected to 
acute global I/R during cardiac bypass surgery, significant elevations in plasma levels of 
eRNA and TNF-α were found. Moreover, following in vivo myocardial I/R in mice or I/R 
induced in the isolated Langendorff-perfused rat heart, both eRNA levels and cardiac injury 
markers were increased. Similarly, in cardiomyocytes subjected to hypoxia, eRNA was 
released resulting in TNF-α liberation through the activation of TNF-α converting enzyme 
(TACE). Conversely, TNF- promoted further eRNA release especially under hypoxia, 
feeding a vicious cell damaging cycle during I/R with the massive production of oxygen 
radicals. The administration of RNase1 or TAPI (a TACE-inhibitor) prevented cell death and 
reduced myocardial infarction. Likewise, RNase1 significantly reduced I/R-mediated energy 
exhaustion, opening of the mitochondrial permeability transition pore as well as oxidative 
damage in cardiomyocytes.  
Conclusions - RNase1 and TACE-inhibition provide novel therapeutic strategies for 
counteracting the adverse eRNA-TNF- interplay which occurs during I/R, thereby 
preventing cell death, limiting myocardial infarct size and preserving cardiac function. This 
newly discovered fundamental pathogenic mechanism of I/R injury is likely to operate in 
other organs and tissues as well. 
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Introduction 
Cardiomyocyte death occurring during acute myocardial infarction has a significant impact on 
the quality of life and survival of patients suffering from coronary artery disease, the most 
eminent single cause of death worldwide1. Severe myocardial ischemia secondary to a 
thrombotic coronary occlusion at the site of a ruptured atheromatous plaque results in 
extensive cardiomyocyte death involving most of the area at risk unless coronary blood flow 
is rapidly restored by pharmacological or mechanical interventions2. However, although early 
reperfusion salvages viable myocardium and limits infarct size and markedly improves the 
prognosis of patients with acute myocardial infarction, its beneficial effect is limited by the 
occurrence of additional cardiomyocyte death during the initial minutes of reflow, a 
phenomenon described as lethal ischemia/reperfusion (I/R) injury3. This paradoxical 
phenomenon, has largely been studied in experimental animal models and is known to be 
caused by a network of mechanisms causing Ca2+-overload4, mitochondrial permeabilization5, 
6 or ATP-dependent hypercontracture7, 8 that may limit myocardial salvage achieved by 
reperfusion9. Experimental studies have convincingly demonstrated that infarct size can be 
markedly reduced by therapeutic interventions applied at the time of reperfusion, such as 
ischemic postconditioning10 and diverse pharmacological interventions aimed to improve 
intracellular calcium handling and reduce proteolytic activation. Moreover, heart protection 
was experimentally achieved by reduction of hypercontracture and mitochondrial 
permeability transition11, modulation of Na+/H+ ion exchanger12 or application of particulate 
guanylyl-cyclase agonist13: However, none of these approaches have been introduced into 
clinical practice. Nevertheless, application of non-invasive intermittent limb I/R (designated 
remote ischemic preconditioning) either applied prior to heart operations14 or applied by a 
paramedic to patients with ST-Segment elevation myocardial infarction (STEMI)15 upon 
primary percutaneous coronary intervention (PPCI) have recently been found to be beneficial 
for the outcome of cardiac ischemic damage. 
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Experimental studies thus far have not taken into account that factors released from the 
damaged cardiac tissue itself may have detrimental effects on reperfused cardiomyocytes and 
contribute to lethal reperfusion injury and final infarct size. Although it is well known that 
disrupted cells may release cytosolic proteins during reperfusion, such as creatine kinase or 
cardiac troponins, these and other factors have only been used for diagnostic evaluation16, 17. 
Another component that is detectable in the extracellular space during tissue hypoxia or cell 
damage are ribonucleic acids (RNA), which are released by damaged cells and designated as 
extracellular RNA (eRNA)18. The majority of eRNA consists of ribosomal RNA, which binds 
to different basic proteins in blood plasma or on cell surfaces, and thereby promotes a variety 
of extracellular functions, particularly related to vascular diseases19, 20. These include 
activation of blood coagulation / thrombosis, release of TNF- and other cytokines as well as 
promotion of inflammatory processes, such as leukocyte trafficking21. Here, we demonstrate 
an obligate role for eRNA and TNF- as early alarm signals in cardiac tissue damage that 
determine the cell fate during cardiac I/R. Consequently, in the current study, we demonstrate 
that the administration of ribonuclease1 (RNase1) to inhibit eRNA or an antagonist of TNF-
-converting enzyme successfully reduced pathological parameters that are characteristic of 
I/R injury and substantially improved the early post-ischemic functional myocardial recovery.  
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Material and Methods 
Extracellular RNA (eRNA) quantification  
eRNA was quantified in plasma obtained from eight patients undergoing cardiac surgery (who 
all gave written informed consent, approved by the Ethics Committee, Medical Faculty, 
Justus-Liebig-University, Giessen; file number 166.11), in mice plasma, in the perfusate 
obtained from the isolated Langendorff heart as well as in conditioned medium from rat 
cardiomyocytes using the Master PureTM RNA Purification kit (Epicentre Biotechnologies). 
Total RNA concentration was quantified with NanoDrop ND-2000 (peqLab Biotechnologie 
GmbH). RNase1 activity was quantified in human plasma or perfusate by an enzymatic assay 
as described22. 
 
Treatment with RNase 1 or RNase-inhibitor (RI) after induction of ischemia / 
reperfusion (I/R) in mice. 
The established in vivo experimentation was exactly carried out as previously described23. 
Animals were treated with a continuously treated (started three days before surgery) with 
RNase1 (Fermentas®, 100 μg/mouse) or RNase Inhibitor (RiboLock, Fermentas®, 80 
U/mouse) via a subcutaneously implanted miniature infusion Alzet® osmotic pump (model 
1004). Quantification of the infarcted area and in vivo assessments of cardiac functions were 
done as described23. All animal experiments and study protocols were approved by local 
authorities of the RWTH Aachen, complying with Romanian and German animal protection 
laws. Experiments involving TNF-deficient mice (TNF-KO) were approved by the Health 
Science Faculty Animal Ethics Committee, University of Cape Town. Animals were housed 
and treated in accordance with the Guide for Care and Use of Laboratory Animals (Eighth 
Edition), published by the US National Institute of Health Publications. TNF-KO from a 
C57BL/6 genetic background, were a generous gift from Dr. Jacobs and Prof. Ryffel 
(Department of Immunology, University of Cape Town)24.  
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Langendorff heart perfusion system 
Wistar rats (10-12 weeks old; weighing 225–300 g) were specific pathogen free, and kept at 
the animal care facility, Justus-Liebig-University, Giessen, with free access to food and water, 
conforming to the Guide for the Care and Use of Laboratory Animals, National Institute of 
Health (NIH publication no. 85-23, revised 1996). Experiments were performed on isolated 
hearts as previously described25; experimental conditions are outlined in the corresponding 
legends to Figures.  
 
Quantification of cell death 
Lactate dehydrogenase (LDH) activity in the Langendorff-perfusate was spectro-
photometrically measured during the entire reperfusion period of 120 min. Thereafter, hearts 
were cut into four slices and incubated at 37°C for 10 min in 1% triphenyltetrazolium chloride 
(pH 7.4) and imaged under white light to outline the area of necrosis26. LDH release into the 
cardiomyocyte-conditioned medium was assessed by a detection kit (Roche Diagnostics)27.  
 
Isolation of adult mouse and rat cardiomyocytes 
Ventricular heart muscle cells were isolated from 12-weeks old rats or mice as previously 
described28, 29. Following hypoxia, cells were loaded with 0.04% trypan blue and cell viability 
was immediately analyzed using a light microscope at 40× magnification. The number of 
viable (unstained) and nonviable (blue stained) cells was recorded as previously described28.  
 
Isolation of extracellular RNA and DNA for cardiomyocyte treatment 
Following washing of confluent cultures of smooth muscle cells with PBS, total RNA was 
isolated with GenElute Mammalian Genomica RNA Miniprep Kit (Sigma-Aldrich). RNA was 
hydrolysed by incubation with RNase1 (Fermentas®) for 1h at 37°C. Hydrolysed RNA was 
always used at the same concentration as cellular RNA. Total RNA concentration was 
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quantified with the NanoDrop ND-2000 (peqLab Biotechnologie GmbH). The quality of total 
RNA and hydrolysed RNA was determined with the 2100 Bioanalyzer using “Eukaryote total 
RNA Nano Assay” (Agilent Technologies). All chips were done in duplicates. DNA was 
isolated with GenElute Mammalian Genomica DNA Miniprep Kit (Sigma-Aldrich) from 
confluent cultures of smooth muscle cells. Quality of total DNA was confirmed by 
electrophoresis on a 1% agarose gel followed by ethidium bromide staining. 
 
Induction of mitochondrial membrane permeabilization  
The preparation of rat cardiomyocytes and experimental procedures were performed as 
previously described4.  
 
ROS immunolabeling and fluorescent microscopy 
Hearts from the different experimental groups were removed from the Langendorff system, 
weighed and rapidly frozen in liquid nitrogen. In situ reactive oxygen species (ROS) were 
determined by labelling with dihydroethidium as described30.  
 
Quantification of TNF- 
Langendorff heart-perfusates or cardiomyocyte conditioned media were collected and filtered 
through 0.2 μm filter to remove any residual debris with subsequent quantification of TNF- 
(for details see supplementary information). 
 
RNA isolation and Quantitative Real Time PCR analysis (qRT-PCR) 
DNA-free total RNA was extracted from homogenised heart tissue or from cardiomyocytes 
treated under different conditions and lysed using TRIzol® Reagent (Invitrogen, USA). 
Standard procedures were used for qRT-PCR (for details see supplementary information). 
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Western blot analysis 
Homogenised heart tissue or cardiomyocytes treated under different conditions were lysed 
using RIPA buffer and prepared for denaturing SDS gel-electrophoresis and western blotting 
as previously described 21.  
 
Statistics 
Data were analyzed by unpaired Student’s t test or One-way ANOVA analysis of variance 
followed by Tukey's, Dunnett’s or Bonferroni's multiple comparisons test was performed, 
when appropriate, to determine statistical significance of the data differences using GraphPad 
Prism version 6.00 (for details see supplementary information). Results were considered as 
significantly different at p<0.05. 
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Results 
Association between extracellular RNA and TNF- in myocardial ischemia/reperfusion 
injury during cardiac surgery. 
Upon tissue damage or vascular injury, significant amounts of extracellular RNA (eRNA) 
(composed predominantly of 18S and 28S ribosomal RNA) are released that promote 
procoagulant and proinflammatory processes, as was observed in our earlier studies18, 22, 31. To 
characterize the pathogenic situation of cardiac ischemia/reperfusion (I/R) injury in this 
respect, 14 cardiac patients (Supplementary Table 1) were analysed for eRNA and tumor 
necrosis factor-α at different time points during surgery: Blood samples were taken from the 
radial artery, directly before and after aortic clamping as well as from the coronary sinus. 
Figure 1A demonstrates a massive increase by 10 to 20 fold of eRNA (predominantly intact 
18S/28S rRNA) (Figure 1B) and a significant elevation of TNF-α (>7-fold) (Figure 1C) 
particularly in coronary sinus blood after aortic clamping. This indicates that ischemic, albeit 
cardioplegia-protected, human myocardium is a major source of eRNA during cardiac surgery 
which may, in concert with TNF-α, contribute to the pathogensis of I/R injury and myocardial 
infarction. 
 
eRNA promotes I/R injury and myocardial infarction. 
In order to prove the release of eRNA upon ischemic heart disease, a myocardial infarction 
model in mice and the isolated rat Langendorff heart model, exposed to I/R injury, were 
investigated. Following coronary artery ligation in mice for 60 min, eRNA levels were 
significantly elevated during the subsequent 120 min reperfusion phase (Figure 2A). In order 
to delineate the cellular origin of eRNA, RT-PCR analysis was carried out to amplify cell-
specific mRNA that was found associated with the released 18S/28S rRNA (Figure 2B, 
insert). Results indicate that eRNA is derived mainly from cardiomyocytes (expressing 
SERCA32) and to a much lesser degree from smooth muscle cells33 (expressing -smooth 
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muscle actin) and myofibroblasts (expressing bHLH transcription factor - Tcf2134) (Figure 
2B).  
After excision and perfusion equilibration of isolated rat hearts on the  Langendorff 
apparatus, blood-free perfusion was arrested for 45 min to achieve global ischemia and 
thereafter, reperfusion was resumed  for 120 min. At the start of the reperfusion phase, a 
significant increase in eluted eRNA was observed (Figure 2C), together with other markers 
of myocardial injury such as lactate dehydrogenase (LDH), cardiac troponins and creatine 
kinase35 (data not shown). In contrast to the latter parameters, a second washout peak of 
eRNA during reperfusion between 15 and 60 min was noted that related to more than 60% of 
the totally recovered eRNA. Analysis of eRNA collected from the entire 120 min reperfusion 
phase revealed a significant portion of microparticle-associated eRNA (Figure 2C, insert). 
To further delineate these findings in a cell culture model, a significant increase in the 
accumulation of eRNA in the supernatants of isolated cardiomyocytes, exposed to hypoxia for 
1h, as compared to 3h of normoxia, was observed (Figure 2D). Moreover, exposure of cells 
towards TNF- significantly enhanced the eRNA release, both under normoxic and hypoxic 
conditions. 
 
Hypoxia and eRNA promote cardiac I/R-induced TNF- release. 
To define the conditions of I/R injury under which TNF-α release occurs, in vivo, ex vivo and 
in vitro experiments were performed. While in the murine heart ligation model under constant 
perfusion no significant TNF-α liberation was observed in the animal circulation (Figure 3A) 
as well as in heart tissue (Figure 3B), exposure to ischemia for 60 min, followed by various 
time intervals of reperfusion (0, 2 and 120 min) all resulted in massive increase in TNF-α 
release with I/R of 60 min/2 min showing the highest value (>20 fold) (Figure 3A). These 
conditions were also associated with a dramatic appearance of TNF-α in heart tissue of these 
animals (Figure 3B). While the administration of RNase1 resulted in a drastic reduction of 
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TNF-α release and tissue deposition, the application of an RNase inhibitor (RI) had no 
significant influence on the eRNA/hypoxia-induced liberation of TNF-α. 
Upon I/R exposure in isolated rat hearts, significantly increased levels of TNF- were 
detectable in the perfusate during the initial 15 min reperfusion phase in accordance with a 
report in which the gene for this cytokine was found to be transcribed during this I/R phase36. 
Treatment with RNase1 reduced the level of TNF- almost to background values (Figure 
3C), and after 120 min reperfusion, TNF- mRNA was significantly decreased in the RNase1 
treatment group (Supplementary Figure 1A). In contrast, administration of RI had neither 
influence on liberation of TNF- nor on its mRNA expression when compared to the I/R 
group. 
In previous studies, we have demonstrated that exposure of monocytes to eRNA 
resulted in the induction of TNF- release, which largely relied on the sheddase TNF--
converting enzyme (TACE/ADAM17)21. Likewise, upon stimulation of cardiomyocytes by 
eRNA under normoxic conditions, a significantly enhanced release of TNF- was noted, 
while in the presence of RNase1, TNF- shedding was minimal. Moreover, even under 
control conditions, RNase1 kept the level of TNF- to a minimum (Supplementary Figure 
1B). eRNA-induced TNF- liberation was confirmed by data from a cytokine profile array, 
showing a significant increase of TNF- under conditions of normoxia and hypoxia 
(Supplementary Figure 1C). Moreover, upon incubation of cardiomyocytes with eRNA for 
1h under hypoxia, a significantly elevated TNF- release was noted that was totally prevented 
by RNase1 treatment (Figure 3D). RNase1 alone was also effective under hypoxia as 
significantly reducing the level of released TNF- (Figure 3D). 
 
 
Production of reactive oxygen species (ROS) during I/R injury and prevention by RNase1. 
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The production of ROS during ischemic heart disease is a causally-related hall-mark in the 
pathogenesis of myocardial infarction, playing a significant role in damaging the heart during 
I/R37, 38. Upon exposure of mice to 60 min regional ischemia (by coronary artery ligation), 
followed by different time intervals of reperfusion, inspection of heart tissue by confocal 
microscopy revealed a markedly disturbed cardiomyocyte structure, accompanied by a 
significant elevation of ROS, which were found at intra-nuclear sites overlapping with the 
DAPI stain for condensed DNA, both in (Figure 4A). The same holds true when tissue 
samples from the isolated Langendorff heart model, under conditions of 45 min ischemia and 
various reperfusion intervals, were inspected (Figure 4B). In contrast, in RNase1-treated 
animals/isolated hearts, not only was the tissue architecture greatly preserved, but the 
fluorescence intensity of ROS was low, similar to control sections, not exposed to I/R. 
Cardiac tissue content of ROS (209 ± 11 AU/m2) in I/R hearts was reduced upon RNase1 
treatment to 70 ± 12 AU/m2 (P<0.001).  As expected, RI treatment did not prevent tissue 
destruction, and ROS accumulation was discernible as in the non-treated I/R injury groups.  
To further substantiate the influence of anti-oxidant enzymes in cardiomyocytes on 
ROS production, RT-PCR analysis of peroxiredoxin 3 and isoforms of superoxide dismutase 
(SOD), representing cytoplasmic SOD1, mitochondrial SOD2 and extracellular SOD3, was 
performed in the Langendorff heart model as well as in isolated cardiomyocytes, exposed to 
the ischemia-related protocols. While low mRNA levels of these antioxidant enzymes were 
found in the isolated heart after 120 min reperfusion only, administration of RNase1 in 
isolated hearts submitted to I/R resulted in significantly elevated mRNA levels of these 
enzymes, particularly peroxiredoxin 3 and SOD 2 (Supplementary Figure 2A). Likewise, 
upon exposure of isolated cardiomyocytes towards eRNA or TNF-, respectively, for 3h 
under normoxia, significantly reduced mRNA levels of the indicated antioxidant enzymes 
were found (Supplementary Figure 2B), whereas RNase1 application fully restored their 
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expression at normal values. The administration of the TACE-inhibitor TAPI in isolated 
cardiomyocytes led to a superimposable beneficial restoration of mRNA expression of the 
antioxidant enzymes as well (Supplementary Figure 2B). 
 
RNase1 protects against cardiac I/R injury and reduces infarct size. 
Following induction of acute cardiac I/R injury in the mouse model, infarct size expressed as 
a percentage of the area of risk was smaller in hearts administered RNase1 when compared to 
the application of buffer alone or RI, respectively (Figure 5A), indicative of the causal 
contribution of eRNA to cardiac tissue damage. Likewise, vehicle-treated mice after 14 days 
of reperfusion developed myocardial infarcts comparable to the RI-treated group (16 ± 3% vs. 
15 ± 2%), whereas the RNase1 treatment group (3 ± 1%) was protected against infarct 
development (Figure 5B). Intra-ventricular measurements revealed a significant decrease in 
left ventricular developed pressure, contraction and relaxation in the control and RI-treated 
groups, whereas the RNase1-treated group exhibited preserved heart function comparable 
with sham or uninjured mice (Supplementary Figure 3A-C).  
 To characterize the detrimental effects of RNase1 upon physiological parameters in 
the Langendorff heart model under I/R conditions, three groups receiving increasing 
concentrations of RNase1 as well as one RI-group were studied. The drugs were administered 
together with the perfusion buffer prior to the induction of 45 min ischemia (Supplementary 
Figure 4A). Measurements of left ventricular end-diastolic pressure (LVEDP, a measure of 
the magnitude of ischemic rigor contracture) in the RI-group (34 ± 5 mmHg) revealed a 
similar or even higher value when compared to non-treated I/R hearts (26 ± 4 mmHg), 
whereas RNase1 in a concentration-dependent manner significantly reduced the adverse 
outcome of I/R (11 ± 3 mmHg at 10 µg/ml) and was effective over the entire reperfusion 
phase (Supplementary Figure 4B). Similarly, cardiomyocyte hypercontracture (a measure of 
I/R-mediated injury) was significantly reduced in the RNase1-treated groups (30 ± 4 mmHg at 
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10 µg/ml), while RI-administration (104 ± 8 mmHg) resulted in an even worse (although not 
significant) effect when compared to the untreated I/R group (66 ± 9 mmHg) 
(Supplementary Figure 4C).  
Furthermore, only minor quantities of LDH were detectable in all perfusate fractions 
in the RNase1 treatment groups, indicating markedly reduced necrotic cell death, whereas the 
typical early release of LDH following reperfusion was documented in the control and the RI-
treated groups (Figure 5C). The cumulative LDH release was markedly reduced in the 
RNase1 group (44 ± 7 UI/g tissue, vs. 127 ± 32 UI/g tissue in I/R group) (Supplementary 
Figure 4D). Most importantly, RNase1-administration substantially decreased infarct size in 
the isolated heart (23% vs. 66 ± 5%, P<0.001) (Figure 5D), while the application of RI did 
had no effect on these parameters when compared to I/R injury alone. Likewise, in the 
RNase1 treatment group, contractile recovery (expressed as left ventricular developed 
pressure, LVdevP) was significantly improved (73 ± 13% of basal values, vs. 38 ± 12% of 
basal values in I/R group) after 120 min reperfusion (Supplementary Figure 4E). 
 
Cytoprotective functions of RNase1. 
While under normoxia, eRNA, RNase1, RI or DNA did not influence basal LDH release in 
cardiomyocytes, a substantial increase of LDH release was observed upon exposure of cells 
towards 1h hypoxia (Figure 5E). Further addition of eRNA, but not hydrolyzed RNA, DNA 
or RI, respectively, resulted in significantly increased LDH release that was almost 
completely abolished by treatment with RNase1, independent of the presence of exogenous 
eRNA. Moreover, TNF- markedly promoted LDH release, particularly under conditions of 
hypoxia (Figure 5F), similar to the activity of eRNA (see Figure 5E). Simultaneous addition 
of TNF- and eRNA did not further enhance LDH release. Conversely, TAPI significantly 
suppressed eRNA-induced LDH release (Figure 5F), but not to the same extent as it was 
demonstrated for RNase1-treatment in the hypoxia-induced LDH release (see Figure 5E). 
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 Ischemia in the isolated rat heart induced a rapid exhaustion of phosphocreatine as a 
measure of energy depletion with only partial recovery in the control I/R group (45 ± 5%) 
after 15 min of reperfusion, whereas in the RNase1 treatment group intracellular 
phosphocreatine remained elevated at a significantly higher level (73 ± 5%, P=0.032) and 
promoted substantial heart recovery (Supplementary Figure 5A). Since dysregulated 
opening of the mitochondrial permeability transition pore (mPTP) provokes mitochondrial 
dysfunction, which is associated with uncoupled oxidative phosphorylation and ATP 
hydrolysis, cardiomyocyte hypercontracture may ultimately lead to cell death4, 39-41. Exposure 
of cardiomyocytes towards eRNA significantly reduced the time of contracture related to 
mPTP opening (Supplementary Figure 5B) as assessed by the fluorescent dye tetramethyl-
rhodamine-ethylester, which is readily sequestered by healthy mitochondria. In contrast, 
RNase1 abolished this effect as reflected by a value that was indistinguishable from the 
control. Furthermore, TNF- promoted mPTP opening and induced cardiomyocyte 
hypercontracture, which became significant at a concentration of TNF- at 50 ng/ml; anti-
TNF- reversed this effect (Supplementary Figure 5C). As an established protective agent, 
cyclosporin-A markedly prolonged the time to cardiomyocyte contracture, as expected. 
 
Prevention of cardiomyocyte death by inhibition of TACE/ADAM17. 
To specify the mechanism underlying eRNA-induced liberation of TNF- and the subsequent 
adverse interplay of both components, the role of the metalloproteinase TACE/ADAM17 was 
explored in the established ex vivo and in vitro models. In the isolated rat heart, TNF- 
release (maximal peak, 85 ± 10 pg/min vs. pre-ischemic values 12 ± 5 pg/min) during the 
initial reperfusion phase was significantly reduced upon treatment with TAPI (22 ± 8 pg/min) 
(Figure 6A). Likewise, in isolated cardiomyocytes, eRNA-induced TNF- release was 
significantly prevented in the presence of the metalloproteinase inhibitors GM6001 or TACE-
16 
 
specific TAPI (Figure 6B). Furthermore, since activation of the NF-κB pathway was 
considered to be related to eRNA activity as well, TNF- liberation was also blocked by the 
IκB phosphorylation inhibitor Bay11-708210 (Bay11). Neutralising antibodies against TNF- 
completely blocked the TNF- release mediated in the absence or presence of eRNA (Figure 
6B). These findings were corroborated by the observation that TAPI-treatment of the isolated 
rat heart during an interval of 30 min prior to the ischemic phase significantly decreased LDH 
release in comparison to the untreated I/R group (Figure 6C). Furthermore, as compared to 
isolated wild-type cardiomyocytes, in TNF-α knockout cells, cell viability upon exposure to 
hypoxia decreased in a similar manner, but was not further reduced in the presence of eRNA 
(Figure 6D), indicating the lack of TNF-α liberation due to the deficiency of the cytokine. 
 Using confocal microscopy to inspect I/R-exposed heart tissue as demonstrated before 
(see Fig. 4), administration of TAPI lead to the preservation of the cardiac tissue architecture, 
and fluorescence intensity of ROS was low as in the non-I/R group (Supplementary Figure 
6A). ROS content (211 ± 17 AU/µm2) in I/R hearts was reduced upon TAPI-treatment to 91 ± 
10 AU/µm2 (Supplementary Figure 6B), indicative of a similar protective role of this 
TACE-inhibitor as documented for RNase1. 
 
The eRNA -TNF- interplay promotes cardiac I/R-induced inflammation. 
Upon ischemia in the isolated rat heart, the expression of the pro-inflammatory cytokine 
MCP-1 as well as iNOS was significantly increased, whereas treatment with RNase1 but not 
with RI prevented this effect (Figure 6E). Likewise, stimulation of isolated cardiomyocytes 
with eRNA or TNF- markedly increased the expression of MCP-1 and iNOS (Figure 6F). In 
contrast, administration of RNase1 or TAPI, respectively, prevented the increase in mRNA 
levels of these inflammatory factors. Finally, Western blot analysis revealed that I/R injury in 
the isolated rat heart induced a significant decrease in IκB- protein production, whereas 
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RNase1 treatment resulted in retaining the inactive NF-κB dimer by maintaining IκB- in the 
non-phosphorylated state. Together, these data document the damaging role of eRNA and 
TNF-α in ischemia-related cardiac injury in different experimental models and propose a 
substantial protective function for RNase1 and TAPI. 
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Discussion 
In the present study, novel mechanistic insights into the process of cardiac I/R injury that are 
governed by the endogenous extracellular RNA/RNase system were obtained. Moreover, the 
interplay between eRNA-dependent and TNF--related pathomechanisms characterized in 
this study may not be limited to ischemic heart disease but may be applied generally to 
ischemia-mediated damage of other organs or tissues as well, such that interventions with 
RNase1 or TACE-inhibitors would definitely provide new regimens for cytoprotection in 
general.   
 The rationale for studying the role of eRNA and TNF-α in ischemic heart disease was 
based upon our previous findings that these poly-anionic compounds promoted arterial 
thrombosis18, induced the release of cytokines (including TNF-α), and served to elevate 
vascular permeability and edema formation in vivo42. Collectively, these functional activities 
of eRNA were largely inhibited by RNase1, which thereby plays a prominent role as a vessel-
and tissue-protective agent43. Moreover, in cardiac patients undergoing cardiac bypass 
surgery, in which the heart is subjected to IRI, significantly elevated levels of eRNA (>20 
fold) and TNF-α (>7-fold) were found in the present study, especially in coronary sinus blood 
before unclamping as compared to peripheral arterial blood. These data indicate massive 
release of these components particularly during an ischemic phase and are in accordance with 
earlier findings demonstrating elevated levels of TNF- and IL-6 in the coronary sinus blood, 
suggestive for these authors to conclude that the lungs may consume rather than release 
proinflammatory cytokines in the early phase of cardiac reperfusion44.  
 In fact, the eRNA - TNF- relation in the coronary sinus may play an important role in 
the inflammatory response after aortic unclamping, not only because it may directly induce 
symptoms, but also because it may trigger the release of other cytokines, such as IL-6, IL-8 or 
IL-1044-46. In other reports, inflammatory responses were found to be the primary cause of 
microvascular incompetence in I/R injury, and global myocardial ischemia during aortic 
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cross-clamping seems to be one of the crucial pathogenetic factors in cardiac cytokine release 
and the “postperfusion syndrome” upon cardiopulmonary bypass45, 46. Together, these 
findings prompted us to further unravel the possible molecular interplay between eRNA and 
TNF-α under conditions of cardiac I/R injury in various experimental models. 
 In fact, acutely elevated levels of eRNA, both free and in association with 
microparticles, were found upon onset of reperfusion in the isolated rat heart model as well as 
in hypoxia-exposed cardiomyocytes in accordance with a recent report demonstrating the 
release of tissue factor-bearing microparticles from cardiomoycytes under inflammatory 
conditions47. Likewise, in acute models of vessel stenosis or chronic models of atherosclerosis 
in mice, we observed increased plasma and tissue concentrations of eRNA33. In the 
Langendorff heart model, the initial reperfusion-dependent washout of eRNA together with 
cardiomyocyte-specific markers such as creatine kinase or troponins was followed by a 
second peak of eRNA, whereby the vast majority of this 18S/28S rRNA material was derived 
from cardiomyocytes. Thus, unlike creatine kinase, troponins or LDH, eRNA remains to be 
released into the perfusate over an appreciable period of time where it can directly or 
indirectly affect cellular functions.  
 Since in isolated cardiomyocytes the combined action of TNF-α and hypoxia provoked 
eRNA release as well, we propose a reciprocal induction between eRNA and TNF-α that is 
particularly relevant under ischemic conditions. In fact, in the in vivo as well as in the ex vivo 
cardiac I/R injury model, substantial amounts of TNF-α were released and became deposited 
in cardiac tissue, whereas these TNF-α values remained almost at control level in the presence 
of RNase1. Collectively, these findings support our contention of an eRNA-promoted 
liberation of TNF-α and its reciprocal amplification in a positive feedback mechanism, 
particularly under conditions of I/R injury, with the result of generating appreciable amounts 
of the cytokine. 
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 Since eRNA, in association with inflammatory processes, may provoke the release of 
TNF- via a proteolytic shedding reaction, involving the metalloproteinase TACE21, we 
tested whether this mechanism would apply to the setting of cardiac I/R injury as well. 
Indeed, TAPI not only prevented the generation of TNF-α in the ex vivo isolated heart model 
or in cardiomyocyte cultures, but also reduced cell death in these systems by blocking LDH-
release and reducing the expression of damaging iNOS or MCP-1. In fact, the influence of 
TAPI on the outcome of these processes, all contributing to cardiac I/R injury and organ 
damage, was qualitatively superimposable with the outcome of RNase1 administration, 
indicative for the fact that a direct eRNA – TNF-α interplay is operative as pathological 
trigger. 
 Another group of major inducers of cellular damage under conditions of cardiac I/R 
injury are ROS, and their prominent contribution to organ damage is without doubt. Yet, the 
causal molecular relations that would lead to massive ROS generation under pathological 
conditions are incompletely understood. Here, we present strong evidence, both in the in vivo 
and ex vivo experimental model, that the elevation of ROS in plasma or perfusate as well as in 
association with the damaged myocardium was substantially reduced or prevented by RNase1 
as well as by TAPI. Thus, it is concluded that the proven eRNA-TNF-α interplay provides a 
major stimulus for ROS production and deposition. Mechanistically, in combination with 
hypoxia/ischemia, eRNA provoked a marked reduction in the expression of antioxidant 
enzymes, indicative of the fact that such endogenous protective factors become down-
regulated under stress conditions. Both, RNase1 or TAPI could reverse this effect by inducing 
the expression of such enzymes like peroxiredoxin 3 or the three isoforms of SOD in the 
Langendorff heart model or in isolated cardiomyocytes, respectively. In addition, RNase1 or 
TAPI reduced the expression of iNOS and MCP-1, factors which are known to be involved in 
mediating cell-damaging signals in cardiomyocytes. Together, these data strongly imply an 
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eRNA - TNFα interplay that appears to feed a vicious circle, culminating in ROS production 
and cardiomyocyte death.  
 The adverse outcome during I/R in the isolated rat heart as well as under hypoxic 
conditions in cardiomyocytes in response to eRNA in concert with TNF-α was also reflected 
by their negative influence on physiological cell parameters, including left ventricular-
developed pressure, cardiomyocyte hypercontracture and mPTP opening. Here, administration 
of RNase1 resulted in markedly reduced contractility and left ventricular end-diastolic 
pressure (as a measure of the magnitude of rigor contracture) of the heart, as well as in very 
low levels of LDH in the perfusate as a general marker for necrotic cell death. Together with 
the massive reduction of ROS in cardiomyocytes as well as the preservation of tissue 
architecture, the multitude of physiological parameters that were protected by application of 
RNase1provide compelling evidence for its causative relation to tissue protection. Although it 
is tempting to assume that the beneficial effects of RNase1 treatment may depend on certain 
RNA degradation products such as adenosine48, 49, we found no evidence for this relation. 
Likewise, 8-sulfophenyltheophylline (8SPT) did not influence the infarct size-reducing effect 
of RNase1, and 8SPT alone did not affect the control infarct size (Supplementary Figure 7).  
Also, it should not be ignored that low doses of TNF-α may contribute to ischemic 
preconditioning protection by a direct effect on mitochondria36,37: In contrast to intervention 
with antibodies against TNF-α that would capture the entire pool of the cytokine and may 
induce adverse effects38, the treatments with RNase1 and TAPI in this study prevented 
excessive TNF-α production, but left sufficient amounts of the cytokine, altogether supporting 
a protective outcome. 
 Finally, the overall measure of organ damage in cardiac I/R injury is ultimately 
quantitated by the degree of cell death and the respective infarct size. Both, RNase1 as well as 
TAPI significantly prevented LDH-release, albeit to a different degree. Here, RNase1 was 
superior to TAPI, particularly under hypoxic conditions, indicative for the fact that eRNA 
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indeed serves as initial upstream inducer of TNF-α liberation. Moreover, quantitation of 
infarct size in the acute or chronic in vivo disease model or the ex vivo Langendorff system 
revealed a massive protective effect in tissue recovery upon RNase1 administration. Thus, 
RNase1 as well as TAPI appear to be evidenced-based new protective drugs to limit cardiac 
infarct size, dependent on the here presented pathogenetic mechanisms. In addition, during 
coronary vessel canalization these drugs may be administered alone or together with a stent-
operating procedure to significantly reduce or prevent the pathological outcome of ischemic 
heart injury.  
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Legends to Figures 
Figure 1. Association between extracellular RNA and TNF- in myocardial ischemia/ 
reperfusion injury during cardiac surgery. (A) Extracellular RNA and (C) TNF- were 
quantified in plasma from cardiac patients undergoing surgery that was withdraw from radial 
artery (RA) or coronary sinus (CS) at the indicated time points: T0 (anesthesia induction – 
basal level), T1 (thoracotomy), T2 (2 min before aortic clamping), T3 (2 min before aortic 
unclamping), T4 (15 min after aortic unclamping), T5 (30 min after aortic unclamping). Data 
represent mean ± SEM (n=15; *p<0.05, **P<0.01, ***P<0.001, ns=non-significant). (B) 
Representative analysis of patient´s extracellular RNA, isolated from plasma and subjected to 
capillary gel electrophoresis, reveals high RNA stability, indicated by the 28S and 18S rRNA 
bands at each time point.  
 
Figure 2. Release of extracellular RNA during myocardial infarction following I/R. (A) 
Following induction of the in vivo cardiac I/R mice model with 60 min ischemia and 180 min 
reperfusion, plasma extracellular RNA was quantified at the indicated time points. Data 
represent mean ± SEM (n=6 mice per group; **P<0.01, ***P<0.001). (B) After coronary 
ligation for 60 min without reperfusion, the mRNAs of the following genes were quantified 
by real-time PCR to deduce their cellular origin: Sarco-/endoplasmic reticulum Ca2+-ATPase 
(Serca – cardiomyocytes), α-smooth muscle actin (Sma, smooth muscle cells, SMC), bHLH 
transcription factor (Tcf21 – cardiac fibroblast), PECAM-1 (Cd31 - endothelial cells), colony 
stimulating factor 1-receptor (Cd115 – macrophages), neutrophil elastase (Elane – 
neutrophils) and mast cell protease-6 (Mcpt6 – mast cells). Values are expressed as mean 
±SEM (n=6); *P<0.05, **P<0.01, ***P<0.001 vs GAPDH expression. The insert indicates the 
electrophoretic mobility of 28S and 18S rRNA in a representative sample. (C) Isolated rat 
hearts (Langendorff-model) were submitted to I/R (45 min ischemia, followed by 120 min 
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reperfusion), and extracellular RNA was quantified in the effluent fractions for each time 
point. Values are normalized to the effluent protein concentration and represent mean ± SD 
(n=9 hearts) as compared to the minimal values at 3-5 min; *P<0.05, **P<0.01, ***P<0.001. 
The insert indicates the microparticle-associated total RNA that was quantified from collected 
perfusate over 120 min and normalized to the effluent protein concentration. Values represent 
mean ± SD (n=9 hearts); **P<0.01. (D) Extracellular RNA was quantified under normoxia 
(3h) or hypoxia (1h) in supernatants of untreated (-) or TNF-α-treated cardiomyocytes. Values 
represent mean ± SD (n=6); *P<0.05, **P<0.01. 
 
Figure 3. Extracellular RNA potentiates the release of TNF- under hypoxia. (A) After 
induction of the in vivo cardiac ischemia/reperfusion (I/R) mice model, sham-operated or 
coronary occluded animals with the following time intervals of I/R (in min): 60/0, 60/2 and 
60/120, respectively, were left untreated (Buffer) or were treated with RNase1 (100 μg/mice) 
or RNase-inhibitor (RI, 80 U/mice) as indicated, and plasma TNF- was quantified at the end 
of the respective experiment. Data represent mean ± SD (n=6-8 mice per group); *P<0.05, 
**P<0.01, ns=non-significant. (B) Following induction of the in vivo cardiac I/R (60 min/120 
min) mice model, the presence of TNF- in cryosections from heart tissue was demonstrated 
by confocal microscopy. Representative merged images from immunofluorescence staining 
for TNF- (red), F-actin (green) and nuclear DNA (4′,6-diamidino-2-phenylindole [DAPI], 
blue) are displayed. All images were obtained under identical conditions of confocal laser 
beam intensity and exposure time (n=6). (C) TNF--release was quantified in fractions 
throughout the first 15 min reperfusion period in the Langendorff heart, submitted to the I/R 
protocol in the absence (squares) or presence of 10 µg/ml RNase1 (circles) or 2 U/ml RI 
(triangles). TNF- values are corrected for the respective flow rate and normalized to the 
effluent protein concentration and represent mean ± SD (n=3-6 hearts); #P<0.001 (I/R vs. pre-
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ischemic values); *P<0.001 (I/R+RNase1 vs. I/R). (D) Cardiomyocytes were treated under 
normoxia (3h) or hypoxia (1h) with RNA, hydrolyzed RNA or RNase1 (10 µg/ml), followed 
by analysis of TNF- in corresponding cell supernatants. Values represent mean ± SD (n=3); 
*P<0.05, **P<0.01, ***P<0.001. 
 
Figure 4. Prevention of ROS production by RNase1. (A) After induction of the in vivo 
cardiac I/R mice model, sham-operated or coronary occluded animals with the following time 
intervals of I/R (in min): 60/0, 60/2 and 60/120, respectively, were left untreated (Buffer) or 
were treated with RNase1 (100 μg/mice) or RNase-inhibitor (RI, 80 U/mice) as indicated. (B) 
Isolated Langendorff-perfused hearts were either submitted to 3h perfusion under normoxia 
(control) or exposed to the I/R protocol with the following time intervals of I/R (in min): 45/0, 
45/2, 45/120, in the absence (Buffer) or in the presence of RNase1 (10 g/ml) or RI (2 U/ml) 
as indicated. The distribution of ROS (dihydroethidium, red) production together with 
detection of F-actin (green) and nuclear DNA (DAPI, blue) was quantified by 
immunofluorescent staining in microslices of cardiac tissue in each case. All samples received 
the same manipulation and all images were obtained under identical conditions of laser beam 
intensity and exposure time using confocal microscopy. Values represent mean ± SD (n=6-8 
per group); *P<0.05, **P<0.01, ***P<0.001. Representative images of multiple experiments 
are shown.  
 
Figure 5. Extracellular RNA-induced cell death during hypoxia: Promotion via TNF-α 
and prevention by RNase1 treatment. (A) Following the induction of the in vivo acute 
cardiac I/R mice model, infarct size in mice hearts was quantified after coronary occlusion 
followed by 2h reperfusion in the absence (Buffer) or presence of RNase1 (100 μg/mice) or 
RNase-inhibitor (RI, 80 U/mice), respectively. Representative pictures show myocardial 
infarct size in heart sections indicated by dual staining with 2,3,5-triphenyltetrazolium (TTC) 
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and Evans blue. (B) Following the induction of the in vivo long-term cardiac I/R mice model, 
histo-morphological analysis was used to evaluate infarct size in mice hearts in the absence 
(without I/R) or presence (I/R) of coronary occlusion followed by 14 days of reperfusion. In 
comparison to sham-operated animals, the other groups were continuously treated with buffer 
only or with RNase1 (100 μg/mice) or RNase-inhibitor (RI, 80 U/mice), respectively, by 
infusion via subcutaneously implanted osmotic pump. Representative pictures show 
myocardial infarct size in heart sections indicated by Gomori 1-step stain. Data represent 
mean ± SEM (n=6-8 mice per group; *P<0.05, ***P<0.001, ns=non-significant). (C) Isolated 
rat hearts (Langendorff-model) were submitted to perfusion only under normoxia (Control) or 
submitted to I/R (45 min/120 min) in the absence (Buffer) or presence of 10 µg/ml RNase1 or 
2 U/ml RI, respectively. Release of lactate dehydrogenase (LDH) during 120 min reperfusion 
was measured in the absence (Buffer) or presence of different doses of RNase1 or RI (2 U/ml) 
as indicated. LDH activity was quantified for each time point and normalized to the tissue 
weight.  Values represent mean ± SEM (n=6-9 hearts); *P<0.05, **P<0.01, ***P<0.001. (D) 
Infarct size was quantified by the TTC reaction in heart sections and expressed as the 
percentage of necrotic tissue with respect to total ventricular mass in the different treatment 
groups indicated. Values represent mean ± SD (n=6-9 hearts); **P<0.01, ***P<0.001, 
ns=non-significant. (E) Release of LDH from cardiomyocytes was quantified as an index of 
sarcolemmal rupture after treatment with RNA (10 g/ml), hydrolyzed RNA (10 µg/ml), with 
RNase1 (10 g/ml), RNase-Inhibitor (RI, 40 mU/ml) or DNA (10 g/ml), respectively, under 
normoxia (3h) or hypoxia (1h, grey zone) as indicated. Values represent mean ± SD (n=4); 
**P<0.01, ***P<0.001, ns=non-significant. (F) LDH release was measured in the 
supernatants of cardiomyocytes after treatment with RNA (10 g/ml) or TNF- (20 ng/ml) in 
the absence (-) or presence of TAPI (10 M) under normoxia (3h) or hypoxia (1h, grey zone), 
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respectively. Values represent mean ± SD (n=3, each in triplicate); *P<0.05, **P<0.01, 
***P<0.001, ns=non-significant.  
 
Figure 6 Inhibition of metalloproteinases prevents cell death and TNF-α release. (A) 
Release of TNF- was quantified in the perfusate fractions throughout the 40 min 
stabilization and first 15 min reperfusion period in Langendorff hearts submitted to I/R 
protocol alone or after administration (arrow) of TAPI (1 M). TNF- values are corrected 
for respective flow rate and normalized to the effluent protein concentration and represent 
mean ± SD (n=3 hearts); #P<0.001 (I/R vs. pre-ischemic values); *P<0.001 (I/R+RNase1 vs. 
I/R). (B) Cardiomyocytes were treated for 3h under normoxia or in the absence (-) or presence 
of RNA (10 g/ml, grey zones) with GM6001 (10 g/ml), TAPI (10 M), Bay11 (100 M) or 
anti-TNF- (25 g/ml), respectively, followed by quantification of TNF- protein in the 
corresponding cell supernatants. Values represent mean ± SD (n=6); *P<0.05, ***P<0.001. 
(C) LDH release was quantified in the perfusate fractions throughout the 40 min stabilization 
and first 15 min reperfusion period in Langendorff hearts submitted to I/R protocol alone or 
after administration (arrow) of TAPI (1 M).  LDH values are normalized to the tissue weight 
and represent mean ± SD (n=3 hearts); *P<0.05, **P<0.01 vs I/R. (D) Cell viability was 
measured in freshly isolated cardiomyocytes from wildtype (WT) and TNF-α-/- mice under 
normoxia or subjected to hypoxia (grey zone) for 2h in the absence (-) or presence of 
extracellular RNA. Data represent mean  ± SEM (n=6); **P<0.01, ***P<0.001, ns=non-
significant. (E) Changes in the cellular mRNA levels of inducible NO-synthase (iNOS) and 
monocyte chemotactic protein-1 (MCP1) were quantified by RT-PCR in isolated rat hearts 
perfused for 3h under normoxic conditions (control) or submitted to the I/R protocol alone or 
in the presence of 10 µg/ml RNase1 or 2 U/ml RI, respectively. (F) Changes in cellular 
mRNA levels of iNOS and MCP1 in cardiomyocytes, untreated (control) or treated with 10 
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µg/ml extracellular RNA, 10 µg/ml RNase1, 20 ng/ml TNF-α or 10 M TAPI, respectively, 
for 3h under normoxia were quantified by RT-PCR. Data in (E) and (F) indicate changes in 
the ratio between target and hprt mRNA relative to the levels in control cells or left ventricle 
tissue, respectively, under non-stimulatory conditions and represent mean ± SD (n=6 in 
cardiomyocytes; n=6 in left ventricle tissue); *P<0.05, **P<0.01, ***P<0.001, ns=non-
significant. (G) Isolated rat hearts were perfused 3h under normoxic conditions (control) or 
submitted to the I/R protocol alone or in the presence of RNase1 (10 µg/ml) or RI (2 U/ml), 
respectively, and protein expression of IκB-α and GAPDH in left ventricle tissue was 
quantified in western blots. The bar graphs represent IκB-α levels normalized to GAPDH in 
the different treatment groups. Data represent mean ± SD (n=3); **P<0.01, ***P<0.001, 
ns=non-significant. 
 
Figure 7 Mechanism of extracellular RNA-TNF-α interplay to induce cardiomyocyte 
damage and intervention with RNase1 or TACE-inhibitor.  Upon hypoxia or cardiac 
ischemia (1), cardiomyocyte damage is accompanied by the release of extracellular RNA 
(eRNA) (2). In turn, eRNA promotes TNF--converting enzyme (TACE)-mediated 
proteolytic shedding of TNF- from its membrane-associated proform (3). Active TNF- 
induces intracellular signaling possibly via its receptor (TNF-R1) (4), involving NFκB-
activation/mobilization and resulting in additional cytokine production, in the downregulation 
of antioxidant enzymes such as peroxiredoxin-3 (Prdx3) or superoxide-dismutases (SOD) 1-3 
and the production of reactive oxygen species (ROS) (5). As a consequence, marked 
mitochondrial damage, loss of ATP-production and pathological oscillations of calcium ions 
(due to the opening of the mitochondrial permeability transition pore, mPTP) will lead to cell 
death (6). To complete the vicious circle, TNF- may promote further release of eRNA, 
which may enhance the ongoing cell destruction (7). The administration of RNase1 or TACE-
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inhibitor TAPI will significantly limit or prevent the indicated adverse effects and serve as 
potent interventional strategies in cardio-protection (8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
38 
 
Figure 1         Cabrera-Fuentes et al. 2014 
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Figure 2         Cabrera-Fuentes et al. 2014 
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Figure 3         Cabrera-Fuentes et al. 2014 
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Figure 4         Cabrera-Fuentes et al. 2014 
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Figure 5         Cabrera-Fuentes et al. 2014 
 
 
 
 
 
43 
 
Figure 6         Cabrera-Fuentes et al. 2014 
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Figure 7         Cabrera-Fuentes et al. 2014 
 
